![Melissa M. Yoon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Melissa M. Yoon
Conseiller Juridique Général chez Ambry Genetics Corp.
Postes actifs de Melissa M. Yoon
Sociétés | Poste | Début | Fin |
---|---|---|---|
Ambry Genetics Corp.
![]() Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Conseiller Juridique Général | - | - |
Historique de carrière de Melissa M. Yoon
Anciens postes connus de Melissa M. Yoon
Sociétés | Poste | Début | Fin |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Secrétaire Général | 12/10/2020 | - |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
General Counsel | 1 |
Corporate Secretary | 1 |
Sectorielle
Commercial Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Ambry Genetics Corp.
![]() Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Commercial Services |
Akcea Therapeutics, Inc.
![]() Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Melissa M. Yoon
- Expérience